Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old.
- You have acute myeloid leukemia (AML) with a CBF rearrangement (t(8;21) or inv(16)).
- Your leukemia has a KIT mutation.
- Your AML did not go away with initial treatment (refractory), or it came back after treatment (relapsed).
- You are generally healthy enough for the trial—no uncontrolled infections, serious organ problems, or other cancers being treated.
- You have not taken avapritinib before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
This trial tests whether taking avapritinib (a targeted pill) after a stem cell transplant can help keep leukemia in remission for people whose AML has a KIT mutation. It's a maintenance therapy meant to prevent relapse.
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Hear when a new AML, Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.